AlloCure commences AC607 Phase 2 clinical trial for acute kidney injury AlloCure.

Brenner, M.D., AlloCure President and Chief Executive Officer. We have worked closely with leaders in the field on the design of ACT-AKI, and trial initiation signifies a significant milestone for AlloCure and the individuals we collectively provide. AC607 can be a promising therapeutic candidate for AKI, that effective therapies are required greatly, stated Richard J. Glassock, M.D., Emeritus Professor of Medicine at the Geffen School of Medication at the University of California, Los Angeles. The initiation of ACT-AKI represents a critical step in the development of an innovative therapy for this all-too-common, serious and costly medical condition, for which no approved remedies exist beyond supportive care currently.Related StoriesViralytics enters into medical trial collaboration agreement with MSDCornell biomedical engineers develop 'super organic killer cells' to destroy tumor cells in lymph nodesNew RNA check of blood platelets may be used to detect location of cancerMethods The experts sought patients receiving treatment in the VA Greater Los Angeles Healthcare System, an integrated network of 12 sites serving a racially – and ethnically-diverse populace in Southern California. A random quantity generator was used to recognize African American patients over the age of 45 years and non-African Americans more than 50 years and data was extracted from the VA's electronic medical information. Included subjects were qualified to receive initial CRC screening between January 1996 and October 2012.